AtriCure (NASDAQ:ATRC – Free Report) had its price objective increased by Piper Sandler from $55.00 to $65.00 in a research note published on Wednesday morning, FlyOnTheWall reports. ATRC has been the subject of several other research reports. Needham & Company LLC upped their target price on shares of AtriCure from $60.00 to $68.00 and gave […]
Emerald Mutual Fund Advisers Trust raised its position in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 1.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 411,400 shares of the medical device company’s stock after purchasing an additional 5,700 shares during […]
AtriCure (NASDAQ:ATRC – Get Free Report) announced its quarterly earnings results on Tuesday. The medical device company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.15, Briefing.com reports. The firm had revenue of $100.92 million during the quarter, compared to analysts’ expectations of $97.55 million. AtriCure had a negative net […]
AtriCure (NASDAQ:ATRC – Get Free Report) had its price objective lifted by equities research analysts at BTIG Research from $56.00 to $68.00 in a research report issued to clients and investors on Wednesday, FlyOnTheWall reports. BTIG Research’s price objective points to a potential upside of 17.79% from the stock’s current price. A number of other […]
AtriCure (NASDAQ:ATRC – Get Free Report) posted its earnings results on Tuesday. The medical device company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.15, Briefing.com reports. AtriCure had a negative return on equity of 7.15% and a negative net margin of 7.67%. The company had revenue of […]